Literature DB >> 11701532

New Views of Sickle Cell Disease Pathophysiology and Treatment.

Wendell F. Rosse, Mohandas Narla, Lawrence D. Petz, Martin H. Steinberg.   

Abstract

This review addresses several areas of concern in the care of patients with sickle cell disease. In Sections I and II, the fundamental pathogenetic mechanisms of sickle cell disease and their clinical consequences are discussed. Dr. Narla presents the evidence for abnormal cell adhesiveness by SS cells and Dr. Rosse examines the role of the increased whole blood viscosity. In Section III, Dr. Petz reviews common and uncommon alloimmune consequences of transfusion in sickle cell disease and discusses the diagnosis and management of sickle cell patients with hyperhemolysis after transfusion. In Section IV, Dr. Steinberg gives an update on the use of hydroxyurea in the treatment of sickle cell disease, including the SC and S-beta thalassemia variants.

Entities:  

Year:  2000        PMID: 11701532     DOI: 10.1182/asheducation-2000.1.2

Source DB:  PubMed          Journal:  Hematology Am Soc Hematol Educ Program        ISSN: 1520-4383


  10 in total

Review 1.  Advances in management of sickle cell disease.

Authors:  M B Agarwal
Journal:  Indian J Pediatr       Date:  2003-08       Impact factor: 1.967

Review 2.  Emerging biobehavioral factors of fatigue in sickle cell disease.

Authors:  Suzanne Ameringer; Wally R Smith
Journal:  J Nurs Scholarsh       Date:  2011-01-04       Impact factor: 3.176

3.  Fatal delayed transfusion reaction in a sickle cell anemia patient with Serratia marcescens sepsis.

Authors:  Desiree Seeyave; Ninad Desai; Scott Miller; Sreedhar P Rao; Steve Piecuch
Journal:  J Natl Med Assoc       Date:  2006-10       Impact factor: 1.798

Review 4.  Delayed hemolytic transfusion reaction in sickle cell disease.

Authors:  Leslie P Scheunemann; Kenneth I Ataga
Journal:  Am J Med Sci       Date:  2010-03       Impact factor: 2.378

5.  Effective control of sickle cell disease with hydroxyurea therapy.

Authors:  Harminder Singh; Navin Dulhani; Bithika Nel Kumar; Prabhakar Singh; Pawan Tiwari
Journal:  Indian J Pharmacol       Date:  2010-02       Impact factor: 1.200

6.  Hydroxyurea and a cGMP-amplifying agent have immediate benefits on acute vaso-occlusive events in sickle cell disease mice.

Authors:  Camila Bononi Almeida; Christoph Scheiermann; Jung-Eun Jang; Colette Prophete; Fernando Ferreira Costa; Nicola Conran; Paul S Frenette
Journal:  Blood       Date:  2012-07-25       Impact factor: 22.113

Review 7.  Management of sickle cell disease: a review for physician education in Nigeria (sub-saharan Africa).

Authors:  Ademola Samson Adewoyin
Journal:  Anemia       Date:  2015-01-18

8.  Dynamic deformability of sickle red blood cells in microphysiological flow.

Authors:  Y Alapan; Y Matsuyama; J A Little; U A Gurkan
Journal:  Technology (Singap World Sci)       Date:  2016-02-19

9.  Patients with sickle cell disease taking hydroxyurea in the Hemocentro Regional de Montes Claros.

Authors:  Fernanda Kelle de Souza Santos; Caroline Nogueira Maia
Journal:  Rev Bras Hematol Hemoter       Date:  2011

Review 10.  Hypertransfusion therapy in sickle cell disease in Nigeria.

Authors:  Ademola Samson Adewoyin; Jude Chike Obieche
Journal:  Adv Hematol       Date:  2014-08-07
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.